Caricamento...
PTIP associates with Artemis to dictate DNA repair pathway choice
PARP inhibitors (PARPis) are being used in patients with BRCA1/2 mutations. However, doubly deficient BRCA1(−/−)53BP1(−/−) cells or tumors become resistant to PARPis. Since 53BP1 or its known downstream effectors, PTIP and RIF1 (RAP1-interacting factor 1 homolog), lack enzymatic activities directly...
Salvato in:
| Pubblicato in: | Genes Dev |
|---|---|
| Autori principali: | , , , , , , |
| Natura: | Artigo |
| Lingua: | Inglês |
| Pubblicazione: |
Cold Spring Harbor Laboratory Press
2014
|
| Soggetti: | |
| Accesso online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4265673/ https://ncbi.nlm.nih.gov/pubmed/25512557 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1101/gad.252478.114 |
| Tags: |
Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !
|